Starling Oncology, Inc. STLN
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +21.8% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Return on equity has no reading this year — return on capital employed, just below, still does: -34%.
The 6-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.5 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 |
| Operating income $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Net income $B | −0.1 | −0.1 | −0.1 | 0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −0.54 | −0.71 | −0.92 | −0.21 | −0.16 | −0.24 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — |
| ROE % | — | −213.4 | −92.2 | 0.1 | −16.5 | −40.7 |
| Shares out B | 0.10 | 0.08 | 0.07 | 0.07 | 0.07 | 0.01 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 5 of the 6 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 13 checks were skipped: EPS is not tagged before 2020.